Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovus Pharmaceuticals Inc. (INNV) Message Board

Again, Why would Innovus apply for a trademark (s

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 405
(Total Views: 1207)
Posted On: 03/19/2017 2:32:29 PM
Posted By: Honeycomb777
Again, Why would Innovus apply for a trademark (spend the money) if the FlutiCare name wasn't already approved by the FDA ?

The FDA HAS to be ok with the naming of the product as that is part of their review process. To me, and others can surely weigh in, we are in the final stages here. If no opposition to the name/trademark comes - I think this is the absolute last piece before official FDA approval hits. In other words, it is in my belief that once we get the trademark - a PR WILL happen. I don't exactly know how much time someone could have to oppose this but my guess would be 30 days from when the examiner approved it. Remember, Novalere, went through this process before too but when they sold the rights to Innovus, they (INNV) now started up the trademark review last December. FDA has had to be in touch with them, which makes sense for the Dr. to be so confident ! He wants to hit the ground running and is getting the cash in place IMO.

How much you want to bet that the net of $3.3M will go to a new product launch (Xyralid) AND getting Sensum and Zestra distributed to those 28 EU countries ? Then, when the warrants get exercised, that money will be solely used for Fluti distribution in 2nd half of 2017 as PPS will skyrocket, once approved. 50M warrants x .15 = ~7.5M

Furthermore, IMO, the buyer(s) of this recent offering probably PROMISED to exercise the warrants ASAP which would give INNV the immediate cash. To do this, they negotiated the same price on the 1 and 5 yr warrants at the low 15 cents. DR D knows Fluti makes them profitable sooner rather than later...HE NEEDS THE FUNDS TO GET THE PRODUCT(S) DISTRIBUTED


(1)
(0)




Innovus Pharmaceuticals Inc. (INNV) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us